VIRX - Viracta Therapeutics, Inc.
IEX Last Trade
0.1637
0.012 7.269%
Share volume: 5,457
Last Updated: Fri 27 Dec 2024 08:14:16 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.15
0.01
7.84%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
1.85%
1 Month
60.24%
3 Months
6.76%
6 Months
-59.14%
1 Year
-58.53%
2 Year
-82.31%
Key data
Stock price
$0.16
DAY RANGE
$0.15 - $0.20
52 WEEK RANGE
$0.15 - $1.31
52 WEEK CHANGE
-$58.42
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Mark A. Rothera
Region: US
Website: viracta.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: viracta.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Viracta Therapeutics, Inc. engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir. The company's development pipeline includesvecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510.
Recent news